A NEW ORALLY-ACTIVE OXYTOCIN ANTAGONIST

被引：0
|
作者：
PETTIBONE, DJ
CLINESCHMIDT, BV
KISHEL, M
LIS, EV
REISS, DR
WOYDEN, CJ
BOCK, MG
CHIU, SHL
EVANS, BE
FREIDINGER, RM
HOBBS, DW
KAUFMAN, MJ
THOMPSON, KL
VEBER, DF
WILLIAMS, PD
COOK, MJ
HALUSKA, GJ
NOVY, MJ
LOWENSOHN, RI
机构：
[1] MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065
[2] MERCK SHARP & DOHME LTD,W POINT,PA 19486
[3] OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006
[4] OREGON HLTH SCI UNIV,PORTLAND,OR 97201
来源：
FASEB JOURNAL | 1993年 / 7卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A478 / A478
页数：1
相关论文
共 50 条
  • [41] PHARMACOLOGICAL PROFILE OF A NOVEL, ORALLY-ACTIVE LEUKOTRIENE B-4 ANTAGONIST, SM-15178
    OHMI, N
    TANI, C
    YAMADA, K
    FUKUI, M
    INFLAMMATION, 1994, 18 (02) : 129 - 140
  • [42] A POTENT, ORALLY-ACTIVE, BALANCED AFFINITY ANGIOTENSIN-II AT(1) ANTAGONIST AND AT(2) BINDING INHIBITOR
    DELASZLO, SE
    QUAGLIATO, CS
    GREENLEE, WJ
    PATCHETT, AA
    CHANG, RSL
    LOTTI, VJ
    CHEN, TB
    SCHECK, SA
    FAUST, KA
    KIVLIGHN, SS
    SCHORN, TS
    ZINGARO, GJ
    SIEGL, PKS
    JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (21) : 3207 - 3210
  • [43] AN ORALLY-ACTIVE NONPEPTIDE ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) MARKEDLY REDUCES INJURY IN A RAT MODEL OF COLITIS
    HOGABOAM, CM
    MULLER, MJ
    HUNT, RH
    COLLINS, SM
    GASTROENTEROLOGY, 1995, 108 (04) : A836 - A836
  • [44] N-0840 - A NOVEL, NONXANTHINE, ORALLY-ACTIVE, SELECTIVE ADENOSINE-A1-RECEPTOR ANTAGONIST
    BARRETT, RJ
    WRIGHT, KF
    DROPPLEMAN, DA
    FASEB JOURNAL, 1992, 6 (04): : A1008 - A1008
  • [45] EFFECTS OF QUINOTOLAST, A NEW ORALLY-ACTIVE ANTIALLERGIC DRUG, ON EXPERIMENTAL ALLERGIC MODELS
    KOBAYASHI, K
    HIROI, J
    KISHI, S
    SAWASE, K
    HIRAYAMA, Y
    CHIHARA, S
    IMAI, T
    SHIGI, Y
    SHIMOMURA, K
    KOHSAKA, M
    JAPANESE JOURNAL OF PHARMACOLOGY, 1993, 63 (01): : 73 - 81
  • [46] POTENT, ORALLY-ACTIVE CARBOXYLATE REPLACEMENT ANALOGS OF THE ENDOTHELIN RECEPTOR ANTAGONIST L-749,329
    FITCH, KJ
    WALSH, TF
    TOUPENCE, RB
    WILLIAMS, DL
    NOLAN, NA
    OBRIEN, JA
    PETTIBONE, DJ
    KIVLIGHN, SD
    KRAUSE, SM
    CLAYTON, FC
    ZINGARO, GJ
    SIEGL, PKS
    GREENLEE, WJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 162 - MEDI
  • [47] THE EFFECT OF THE ORALLY-ACTIVE PLATELET-ACTIVATING-FACTOR ANTAGONIST WEB-2086 IN THE TREATMENT OF ASTHMA
    SPENCE, DPS
    JOHNSTON, SL
    CALVERLEY, PMA
    DHILLON, P
    HIGGINS, C
    RAMHAMADANY, E
    TURNER, S
    WINNING, A
    WINTER, J
    HOLGATE, ST
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (05) : 1142 - 1148
  • [48] PROCEEDINGS OF A SYMPOSIUM CEFTIBUTEN - A NEW ORALLY-ACTIVE CEPHALOSPORIN FOR PEDIATRIC INFECTIONS - INTRODUCTION
    NELSON, JD
    MCCRACKEN, GH
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (07) : S76 - S76
  • [49] ANTITHROMBOTIC EFFECTS OF ORALLY-ACTIVE SYNTHETIC ANTAGONIST OF ACTIVATED FACTOR-X IN NONHUMAN-PRIMATES
    YOKOYAMA, T
    KELLY, AB
    MARZEC, UM
    HANSON, SR
    KUNITADA, S
    HARKER, LA
    CIRCULATION, 1995, 92 (03) : 485 - 491
  • [50] POTENCY OF PD155080, AN ORALLY-ACTIVE ET(A) RECEPTOR ANTAGONIST, DETERMINED FOR HUMAN ENDOTHELIN RECEPTORS
    MAGUIRE, JJ
    KUC, RE
    DOHERTY, AM
    DAVENPORT, AP
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 : S362 - S364
12345